Related references
Note: Only part of the references are listed.Biological functions and therapeutic opportunities of soluble cytokine receptors
Juliane Lokau et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2020)
Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-β Mediation
Isaac Hurtado-Guerrero et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Aberrant expression of alternative splicing variants in multiple sclerosis - A systematic review
Michael Hecker et al.
AUTOIMMUNITY REVIEWS (2019)
The metalloprotease ADAM17 in inflammation and cancer
Stefan Duesterhoeft et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients
Paulus S. Rommer et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Multiple Sclerosis
Daniel S. Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Proteolytic Cleavage-Mechanisms, Function, and Omic Approaches for a Near-Ubiquitous Posttranslational Modification
Theo Klein et al.
CHEMICAL REVIEWS (2018)
The emerging role of ADAM metalloproteinases in immunity
Bart N. Lambrecht et al.
NATURE REVIEWS IMMUNOLOGY (2018)
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker
Teresa Orpez-Zafra et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker
Teresa Orpez-Zafra et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Development and validation of an ELISA for quantification of soluble IFN-β receptor: assessment in multiple sclerosis
Teresa Orpez-Zafra et al.
BIOANALYSIS (2015)
Soluble IFN Receptor Potentiates In Vivo Type I IFN Signaling and Exacerbates TLR4-Mediated Septic Shock
Shamith A. Samarajiwa et al.
JOURNAL OF IMMUNOLOGY (2014)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria
Chris H. Polman et al.
ANNALS OF NEUROLOGY (2011)
Validation of immunoassay for protein biomarkers: Bioanalytical study plan implementation to support pre-clinical and clinical studies
Marie-Anne Valentin et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2011)
Alternative splicing in multiple sclerosis and other autoimmune diseases
Irina Evsyukova et al.
RNA BIOLOGY (2010)
The MIQE Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR Experiments
Stephen A. Bustin et al.
CLINICAL CHEMISTRY (2009)
Neutralizing antibodies against IFN beta in patients with multiple sclerosis: A comparative study of two cytopathic effect tests (CPE) for their detection
B. Oliver et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2009)
Measures in the first year of therapy predict the response to interferon β in MS
J. Rio et al.
MULTIPLE SCLEROSIS (2009)
Molecular mechanisms of soluble cytokine receptor generation
Stewart J. Levine
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Alternative isoform regulation in human tissue transcriptomes
Eric T. Wang et al.
NATURE (2008)
The tale of soluble receptors and binding proteins: From bench to bedside
Daniela Novick et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2007)
Interferon-beta - Mechanism of action and dosing issues
Clyde E. Markowitz
NEUROLOGY (2007)
Formation of human IFN-β complex with the soluble type I interferon receptor IFNAR-2 leads to enhanced IFN stability, pharmacokinetics, and antitumor activity in xenografted SCID mice
SD McKenna et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2004)
Regulated proteolysis of the IFNaR2 subunit of the interferon-alpha receptor
AZM Saleh et al.
ONCOGENE (2004)
Consequences of regulated pre-mRNA splicing in the immune system
KW Lynch
NATURE REVIEWS IMMUNOLOGY (2004)
Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity
Y Kawade et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Multiple regions within the promoter of the murine Ifnar-2 gene confer basal and inducible expression
MP Hardy et al.
BIOCHEMICAL JOURNAL (2002)
The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties
MP Hardy et al.
BLOOD (2001)
Share Paper
